Plain-English translation of NCT06277180 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This trial is testing a new imaging scan called 68Ga-TCR-FAPI PET/CT to help surgeons see exactly where medullary thyroid cancer is located before and during surgery. The scan uses a special tracer that attaches to cancer cells, making them easier to spot. Researchers hope this new imaging method will help surgeons remove more cancer while causing less damage to healthy tissue.
Current imaging methods like ultrasound, CT, and MRI sometimes miss areas of medullary thyroid cancer, making it hard for surgeons to know exactly how much tissue needs to be removed. This new imaging scan is designed to show cancer more clearly so surgeons can be more precise and remove all the disease.
You likely qualify if…
You likely don't qualify if…
You will have the new imaging scan before surgery to help your surgeon plan the operation. Based on what the scan shows, your surgeon will remove all the cancer spots that light up on the image. After surgery, you will have follow-up visits to check your blood work and see how well you are recovering, with monitoring continuing for about 2 years to see how long you remain cancer-free.
AI-generated summary from trial data · Jun 13, 2026 · Not medical advice
China